RPG-01-132

RPG-01-132 (0.04-20 μM; 24 h) reduces the yield of infectious DENV2 progeny viruses in wild-type Huh7.5 cells in a concentration-dependent and CRL4^CRBN-dependent manner, with an EC₅₀ of 0.47 μM; however, it shows no significant activity in CRBN-knockout Huh7.5 cells^[1].
RPG-01-132 (30 μM; 24 h) potently inhibits the assembly of DENV2 virions in Huh7.5 cells, resulting in almost complete undetectability of virions in intracellular compartments^[1].
RPG-01-132 (0.156-0.625 μM; 24 h) concentration-dependently restores IFN-β promoter activity suppressed by ectopically expressed DENV2 capsid protein in HEK293 cells, indicating that it can disrupt the interferon antagonism mediated by the capsid protein^[1].
RPG-01-132 (0.04-20 μM; 24 h) exhibits stable, CRL4^CRBN-dependent antiviral activity against all four DENV serotypes at a concentration of 10 μM; compared with wild-type DENV2 16681, it retains considerable capsid degradation activity (DC₅₀ = 1.85 μM) and antiviral activity (EC₅₀ = 0.58 μM) against the ST148-resistant DENV2 16681 C-S34L mutant strain^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.